

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Binimetinib. [Updated 2021 Aug 16]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Binimetinib

Revised: August 16, 2021.

CASRN: 606143-89-9

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of binimetinib during breastfeeding. Because binimetinib is 97% bound to plasma proteins, and the half-life of the drug is 3.5 hours, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 3 days after the final dose. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 2 weeks after the final dose.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Binimetinib

CAS Registry Number

606143-89-9

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors